Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026

About this update from Dogwood Therapeutics, Inc.

ALPHARETTA, Ga., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) ("Dogwood" or the "Company"), a company that focuses on developing first-in-class, new non-opioid medicines to treat pain and neuropathy, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, September 1, 2026 at 10:00 AM Eastern Time, featuring J. Mark Joyce, M.D. (CNS Healthcare), Iain D. Dukes, D.Phil. (OrbiMed Advisors, Chair Dogwood SAB), and Jerry Evarts, Ph.D. (expert CMC Specialist, Dogwood), who will join company management to discuss the unmet need and current treatment landscape for chemotherapy induced neuropathic pain ("CINP"). To register, click here. The event will review the novel role of the NaV 1.7 sodium ion channel in pain signaling, which is key to the initiation and conduction of the electrical signals that the brain interprets as pain. Management will discuss Halneuron®'s selective and differentiated NaV 1.7 mechanism of action as compared to current and future NaV inhibitors. The speakers will also review prior Halneuron® pre-clinical and clinical research and the design and projected treatment outcomes of the ongoing Phase 2b CINP study design. Halneuron® has been tested on more than 800 patients to date, including patients suffering from cancer-related pain and CINP. Guest experts will discuss ion channel therapies as a newer approach to treating chronic pain, as well as the existing unmet medical need in treating CINP. The company will review positive interim results from its ongoing Phase 2b clinical trial in patients with a mean duration of five years of painful neuropathy due to their prior chemotherapy treatment and discuss the advancement of the first ever synthetic formulation of Tetrodotoxin to support Halneuron®'s' Phase 3 development. A live question and answer session will follow the formal presentations. About J. Mark Joyce, M.D. J. Mark Joyce, M.D. became an investigator for CNS Healthcare of Jacksonville in September 2003. He earned his medical degree from the University of Alabama School of Medicine and completed his psychiatry residency training at Emory University School of Medicine in 1992. Board certified in psychiatry, Dr. Joyce has extensive experience in the public mental health field and owned a private practice in Atlanta, Georgia prior to relocating to Jacksonville. About Iain D. D...

View stock analysis, news, and events for Dogwood Therapeutics, Inc.